2020
Clinician perspectives of complementary and integrative medicine (CIM) at an academic cancer center.
Husain M, Rogers S, Klemanski D, Fullmer M, Hreachmack C, Kemper K, Stephens J, Desai P, Lustberg M. Clinician perspectives of complementary and integrative medicine (CIM) at an academic cancer center. Journal Of Clinical Oncology 2020, 38: e24047-e24047. DOI: 10.1200/jco.2020.38.15_suppl.e24047.Peer-Reviewed Original ResearchAdvanced practice providersCIM therapiesComprehensive cancer centerCancer CenterTraditional Chinese medicineSurgical oncologyIntegrative therapiesSolid tumorsAcademic comprehensive cancer centerTertiary comprehensive cancer centerLimited evidence-based dataSymptoms of painPotential drug interactionsRadiation oncologyAcademic cancer centerTreatment-related effectsVitamins/mineralsPatient-clinician communicationEvidence-based dataHematology/oncology fellowsPerspectives of cliniciansMedian age rangeMind-body practicesCIM useMedical oncology
2017
Multispectral Imaging Analysis of Circulating Tumor Cells in Negatively Enriched Peripheral Blood Samples
Miller B, Lustberg M, Summers T, Chalmers J. Multispectral Imaging Analysis of Circulating Tumor Cells in Negatively Enriched Peripheral Blood Samples. Methods In Molecular Biology 2017, 1634: 219-234. PMID: 28819855, DOI: 10.1007/978-1-4939-7144-2_19.Peer-Reviewed Original ResearchMeSH KeywordsBiomarkers, TumorBreast NeoplasmsCarbocyaninesCell CountCell Line, TumorEpithelial Cell Adhesion MoleculeFemaleFluorescent DyesHumansHydrazinesImage Processing, Computer-AssistedIndolesKeratinsLeukocyte Common AntigensLeukocytes, MononuclearLiquid CrystalsNeoplastic Cells, CirculatingOptical ImagingSoftwareSuccinimidesConceptsPeripheral blood samplesBlood samplesPeripheral bloodTumor cellsLiquid biopsyUseful predictive markerSolid tumor malignanciesVariety of disordersUndefined cell typesLow EpCAM expressionSpecific cell surface markersCell surface markersVariety of biomarkersPredictive markerTherapeutic responseSolid tumorsPositive selection technologyDisease statusTumor malignancyFuture validation studiesEpCAM expressionSurface markersMultispectral imaging analysisProtein levelsExact role
2016
Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair
Villalona-Calero M, Duan W, Zhao W, Shilo K, Schaaf L, Thurmond J, Westman J, Marshall J, Xiaobai L, Ji J, Rose J, Lustberg M, Bekaii-Saab T, Chen A, Timmers C. Veliparib Alone or in Combination with Mitomycin C in Patients with Solid Tumors With Functional Deficiency in Homologous Recombination Repair. Journal Of The National Cancer Institute 2016, 108: djv437. PMID: 26848151, PMCID: PMC4948564, DOI: 10.1093/jnci/djv437.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAntineoplastic AgentsAntineoplastic Combined Chemotherapy ProtocolsBenzimidazolesDiarrheaDrug Administration ScheduleFanconi AnemiaFatigueFeasibility StudiesFemaleGenes, BRCA1Genes, BRCA2Germ-Line MutationHumansMaleMiddle AgedMitomycinNeoplasmsPedigreePoly(ADP-ribose) Polymerase InhibitorsRecombinational DNA RepairThrombocytopeniaConceptsPatient tumorsPARP inhibitorsFunctional deficiencySafety/feasibilityDose-escalation trialBRCA germline mutationsCancer patient tumorsClinical Laboratory Improvement AmendmentsArchival tumor materialCombination armEscalation trialAntitumor responseClinical benefitSevere toxicityTumor specimensPatientsDose levelsSolid tumorsGermline analysisGermline alterationsTumor materialTumorsVeliparibBRCA genesGermline mutations
2015
Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary
Mikhail S, Lustberg M, Ruppert A, Mortazavi A, Monk P, Kleiber B, Villalona-Calero M, Bekaii-Saab T. Biomodulation of capecitabine by paclitaxel and carboplatin in advanced solid tumors and adenocarcinoma of unknown primary. Cancer Chemotherapy And Pharmacology 2015, 76: 1005-1012. PMID: 26416564, DOI: 10.1007/s00280-015-2877-6.Peer-Reviewed Original ResearchMeSH KeywordsActivation, MetabolicAdenocarcinomaAdultAgedAntineoplastic Combined Chemotherapy ProtocolsCapecitabineCarboplatinDisease-Free SurvivalDose-Response Relationship, DrugDrug Administration ScheduleEnzyme InductionEsophageal NeoplasmsFatigueFemaleGene Expression Regulation, NeoplasticHematologic DiseasesHumansKaplan-Meier EstimateMaleMaximum Tolerated DoseMiddle AgedNeoplasmsNeoplasms, Unknown PrimaryPaclitaxelPancreatic NeoplasmsProdrugsThymidine PhosphorylaseTreatment OutcomeUp-RegulationYoung AdultConceptsAdvanced solid tumorsII studyUnknown primaryDay 1Phase I/II studySolid tumorsPhase IPhase II patientsAntitumor activityObjective response ratePhase II dosePhase II studyMaximal tolerable doseSynergistic antitumor activityCessation of fundingCapecitabine 750Paclitaxel 60Disease stabilizationAcceptable tolerabilityAdvanced adenocarcinomaPartial responseCarboplatin AUCII patientsTolerable dosePatients
2014
CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth
Mathsyaraja H, Thies K, Taffany D, Deighan C, Liu T, Yu L, Fernandez S, Shapiro C, Otero J, Timmers C, Lustberg M, Chalmers J, Leone G, Ostrowski M. CSF1-ETS2-induced microRNA in myeloid cells promote metastatic tumor growth. Oncogene 2014, 34: 3651-3661. PMID: 25241894, PMCID: PMC4369473, DOI: 10.1038/onc.2014.294.Peer-Reviewed Original ResearchConceptsTumor-infiltrating myeloid cellsMetastatic tumor growthMyeloid cellsMiR-21Breast cancerTumor growthHuman metastatic breast cancerMetastatic tumor burdenMetastatic breast cancerPro-tumor functionsAnti-angiogenic genesAttractive therapeutic targetTumor cell proliferationPro-angiogenic propertiesMature myeloid cellsTumor burdenMonocytes correlatesPoor prognosisMelanoma metastasesMouse modelTherapeutic targetSolid tumorsOncogenic roleSurvival rateTherapeutic efficacyTreatment‐Related Mortality With Everolimus in Cancer Patients
Wesolowski R, Abdel‐Rasoul M, Lustberg M, Paskell M, Shapiro C, Macrae E. Treatment‐Related Mortality With Everolimus in Cancer Patients. The Oncologist 2014, 19: 661-668. PMID: 24794158, PMCID: PMC4041666, DOI: 10.1634/theoncologist.2013-0355.Peer-Reviewed Original ResearchConceptsFatal adverse eventsTreatment-related mortalityCancer patientsAdverse eventsOverall incidenceSan Antonio Breast Cancer SymposiumRole of everolimusControl group patientsMultiple solid tumorsEverolimus administrationGroup patientsCancer SymposiumSubgroup analysisControl armOdds ratioEverolimusFatal eventsClinical OncologyPatientsSolid tumorsPubMed databaseTumor typesIncidenceAmerican SocietySignificant differences
2013
A first-in-human phase I trial of AR-12, a PDK-1 inhibitor, in patients with advanced solid tumors.
Mateo J, De Bono J, Ramanathan R, Lustberg M, Zivi A, Basset D, Ng M, Young A, Garrett M, Decordova S, Raynaud F, Yap T, Zukiwski A, Proniuk S, Shapiro C. A first-in-human phase I trial of AR-12, a PDK-1 inhibitor, in patients with advanced solid tumors. Journal Of Clinical Oncology 2013, 31: 2608-2608. DOI: 10.1200/jco.2013.31.15_suppl.2608.Peer-Reviewed Original ResearchPlatelet-rich plasmaAdvanced solid tumorsAR-12PK variabilitySafety dataFood effectSolid tumorsHuman phase I trialAdequate organ functionECOG PS 0Phase II doseDose-escalation studyPhase I trialDrug-related eventsHuman clinical trialsHigh PK variabilityCOX-2 inhibitory activityMechanism of actionBID cohortQD cohortStable diseaseStudy drugPS 0I trialSingle dose
2011
Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction
Berger M, Dunlea L, Rettig A, Lustberg M, Phillips G, Shapiro C. Feasibility of stopping paclitaxel premedication after two doses in patients not experiencing a previous infusion hypersensitivity reaction. Supportive Care In Cancer 2011, 20: 1991-1997. PMID: 22089428, PMCID: PMC3411299, DOI: 10.1007/s00520-011-1303-9.Peer-Reviewed Original ResearchConceptsInfusion hypersensitivity reactionPaclitaxel-based chemotherapyHypersensitivity reactionsRescue medicationPaclitaxel dosesSecond doseDoses of paclitaxelBreast cancer patientsUse of paclitaxelPotential unwanted side effectsConclusionsIn patientsPrimary endpointSubsequent dosesUnwanted side effectsCancer patientsPremedicationSide effectsPatientsSolid tumorsDoses 3MedicationsChemotherapyDosesHypersensitivityDose
2009
Biomodulation of capecitabine by weekly paclitaxel and carboplatin in patients with advanced solid tumor malignancies: A dose-escalating phase I study
Lustberg M, Nuovo J, Thomas J, Monk P, Kim S, Villalona-Calero M, Bekaii-Saab T. Biomodulation of capecitabine by weekly paclitaxel and carboplatin in patients with advanced solid tumor malignancies: A dose-escalating phase I study. Journal Of Clinical Oncology 2009, 27: 2569-2569. DOI: 10.1200/jco.2009.27.15_suppl.2569.Peer-Reviewed Original ResearchDay 1Common grade 3/4 toxicitiesCapecitabine-based treatmentGrade 3/4 toxicitiesAdvanced solid tumorsExpression of TPThymidine phosphorylase activityAUC 6Carboplatin doseWeekly paclitaxelNeutropenic feverPrior therapyTherapeutic indexCapecitabineDose levelsSolid tumorsDay 8Dihydropyrimidine dehydrogenaseCarboplatinMalignant tissuesPhase IPaclitaxelNeutropeniaPatientsPhosphorylase activity